申请人:Sterling Drug Inc.
公开号:US04264609A1
公开(公告)日:1981-04-28
Amrinone intermediates are prepared by reacting 4-picoline with at least three mole equivalents of phosgene per mole of 4-picoline and excess dimethylformamide to produce N-[3-dimethylamino-2-(4-pyridinyl)-2-propenylidene]-N-methylmethaniminium chloride hydrochloride, then reacting the latter with Q-CH.sub.2 CONH.sub.2 and at least three mole equivalents of base in anhydrous medium and then neutralizing the reaction mixture to produce 5-Q-[3,4'-bipyridin]-6(1H)-one, where Q is cyano or carbamyl. Other aspects of the invention are the separate steps of preparing said iminium salt and then converting it to said 5-Q-[3,4'-bipyridin]-6(1H)-one, and also cardiotonic composition and method for increasing cardiac contractility using said iminium salt or pharmaceutically-acceptable acid-addition salt thereof as the active cardiotonic.
Amrinone中间体是通过将4-吡啶酮与至少三摩尔当量的光气反应,并在过量二甲基甲酰胺存在下制备N-[3-二甲基氨基-2-(4-吡啶基)-2-丙烯基]-N-甲基甲酰胺盐酸盐,然后将后者与Q-CH.sub.2 CONH.sub.2及至少三摩尔当量的碱在无水介质中反应,然后中和反应混合物以制备5-Q-[3,4'-联吡啶]-6(1H)-酮,其中Q为氰基或氨基甲酰基。本发明的其他方面是分别制备所述亚胺盐,然后将其转化为所述5-Q-[3,4'-联吡啶]-6(1H)-酮,以及使用所述亚胺盐或其药学上可接受的酸加成盐作为活性强心剂的心脏强效合成物和增加心脏收缩力的方法。